RU2521338C9 - Способ лечения атрофической возрастной макулярной дегенерации - Google Patents

Способ лечения атрофической возрастной макулярной дегенерации Download PDF

Info

Publication number
RU2521338C9
RU2521338C9 RU2011105409/15A RU2011105409A RU2521338C9 RU 2521338 C9 RU2521338 C9 RU 2521338C9 RU 2011105409/15 A RU2011105409/15 A RU 2011105409/15A RU 2011105409 A RU2011105409 A RU 2011105409A RU 2521338 C9 RU2521338 C9 RU 2521338C9
Authority
RU
Russia
Prior art keywords
drug delivery
delivery system
eye
bevacizumab
dry
Prior art date
Application number
RU2011105409/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2521338C2 (ru
RU2011105409A (ru
Inventor
Майкл Р. РОБИНСОН
Уэнди М. БЛАНДА
Патрик М. ХЬЮС
Джэймс А. БЁРКЕ
Скотт М. Виткап
Original Assignee
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аллерган, Инк. filed Critical Аллерган, Инк.
Publication of RU2011105409A publication Critical patent/RU2011105409A/ru
Application granted granted Critical
Publication of RU2521338C2 publication Critical patent/RU2521338C2/ru
Publication of RU2521338C9 publication Critical patent/RU2521338C9/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2011105409/15A 2008-07-18 2009-07-13 Способ лечения атрофической возрастной макулярной дегенерации RU2521338C9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/176,238 2008-07-18
US12/176,238 US8821870B2 (en) 2008-07-18 2008-07-18 Method for treating atrophic age related macular degeneration
PCT/US2009/050373 WO2010009034A2 (en) 2008-07-18 2009-07-13 Method for treating atrophic age related macular degeneration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2014115647A Division RU2668371C2 (ru) 2008-07-18 2009-07-13 Способ лечения атрофической возрастной макулярной дегенерации

Publications (3)

Publication Number Publication Date
RU2011105409A RU2011105409A (ru) 2012-08-27
RU2521338C2 RU2521338C2 (ru) 2014-06-27
RU2521338C9 true RU2521338C9 (ru) 2014-09-10

Family

ID=41530477

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2011105409/15A RU2521338C9 (ru) 2008-07-18 2009-07-13 Способ лечения атрофической возрастной макулярной дегенерации
RU2014115647A RU2668371C2 (ru) 2008-07-18 2009-07-13 Способ лечения атрофической возрастной макулярной дегенерации
RU2018133133A RU2018133133A (ru) 2008-07-18 2018-09-19 Способ лечения атрофической возрастной макулярной дегенерации

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2014115647A RU2668371C2 (ru) 2008-07-18 2009-07-13 Способ лечения атрофической возрастной макулярной дегенерации
RU2018133133A RU2018133133A (ru) 2008-07-18 2018-09-19 Способ лечения атрофической возрастной макулярной дегенерации

Country Status (11)

Country Link
US (3) US8821870B2 (OSRAM)
EP (4) EP3524270B1 (OSRAM)
JP (3) JP2011528656A (OSRAM)
KR (1) KR20110047196A (OSRAM)
CN (2) CN102159246A (OSRAM)
AU (1) AU2009271168B2 (OSRAM)
BR (1) BRPI0915981A2 (OSRAM)
CA (1) CA2731270C (OSRAM)
ES (3) ES2720882T3 (OSRAM)
RU (3) RU2521338C9 (OSRAM)
WO (1) WO2010009034A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
PL2391419T3 (pl) 2009-01-29 2019-12-31 Forsight Vision4, Inc. Dostarczanie leku do tylnego odcinka
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
IN2012DN03361A (OSRAM) * 2009-10-01 2015-10-23 Evonik Degussa Corp
CN102711756A (zh) * 2010-01-14 2012-10-03 株式会社三和化学研究所 用于预防或治疗伴有眼内血管生成及/或眼内血管通透性增高的疾病的药物
US20130210876A1 (en) * 2010-01-21 2013-08-15 Allergan, Inc Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
BR112012018154A2 (pt) * 2010-01-21 2016-04-05 Allergan Inc agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular
WO2011137363A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
EP2600876B1 (en) 2010-08-05 2015-04-29 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
EP2600812B1 (en) 2010-08-05 2021-09-22 ForSight Vision4, Inc. Apparatus to treat an eye
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
AU2011292160B2 (en) * 2010-08-17 2015-09-03 Ohr Pharmaceutical, Inc. Ophthalmic formulations of squalamine
CN106214321B (zh) 2010-10-15 2018-08-28 科尼尔赛德生物医学公司 用于进入眼睛的装置
WO2012068549A2 (en) * 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
JPWO2012105610A1 (ja) * 2011-02-02 2014-07-03 株式会社三和化学研究所 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
US8715713B2 (en) 2011-04-29 2014-05-06 Allergan, Inc. Solvent cast film sustained release latanoprost implant
CA2838289C (en) * 2011-06-10 2019-09-10 Ramscor, Inc. Sustained release formulations for delivery of proteins to the eye and methods of preparing same
CN103687622A (zh) 2011-06-16 2014-03-26 香港科技大学 含有多个乙烯砜的分子
EP2726016B1 (en) 2011-06-28 2023-07-19 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
WO2013010274A1 (en) * 2011-07-19 2013-01-24 Wilfred Jefferies Methods for diagnosing and treating alzheimer's disease by administering an ανίίangiogenic agent
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
EP2755600B1 (en) 2011-09-16 2021-03-17 ForSight Vision4, Inc. Fluid exchange apparatus
WO2013074840A1 (en) * 2011-11-15 2013-05-23 Allergan, Inc. Treatment of dry age related macular degeneration
WO2014052518A1 (en) 2012-09-27 2014-04-03 Allergan, Inc. Biodegradable drug delivery systems for the sustained release of proteins
EP3721872B1 (en) 2012-11-08 2025-01-22 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
CN102988301A (zh) * 2012-12-26 2013-03-27 温州医学院 一种含贝伐单抗的长效缓释微球的制备方法
US9254409B2 (en) 2013-03-14 2016-02-09 Icon Health & Fitness, Inc. Strength training apparatus with flywheel and related methods
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
EP2991706B1 (en) 2013-05-03 2021-06-23 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
WO2014197317A1 (en) 2013-06-03 2014-12-11 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
EP3016634A2 (en) * 2013-07-05 2016-05-11 Therakine Biodelivery GmbH Drug-delivery composition for topical applications and injections and ophtalmic formulations, method for manufacturing thereof, and methods for delivery a drug-delivery composition
US9782345B2 (en) 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
ES2875878T3 (es) 2013-11-18 2021-11-11 Formycon Ag Composición farmacéutica de un anticuerpo anti-VEGF
CN105848733B (zh) 2013-12-26 2018-02-13 爱康保健健身有限公司 缆绳器械中的磁性阻力机构
US10426989B2 (en) 2014-06-09 2019-10-01 Icon Health & Fitness, Inc. Cable system incorporated into a treadmill
MX2016017028A (es) 2014-06-20 2017-08-07 Clearside Biomedical Inc Canula de diametro variable y metodos para el control de la profundidad de insercion para administracion de medicamentos.
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP2017524034A (ja) 2014-08-08 2017-08-24 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法
USD750223S1 (en) 2014-10-14 2016-02-23 Clearside Biomedical, Inc. Medical injector for ocular injection
CA2977738A1 (en) * 2015-02-26 2016-09-01 Feramda Ltd. Compositions and combinations for the treatment of angiogenesis diseases and disorders
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
EP3973977A1 (en) 2015-03-31 2022-03-30 Ildong Pharm Co., Ltd. Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
WO2016194869A1 (ja) * 2015-05-29 2016-12-08 生化学工業株式会社 グリコサミノグリカン誘導体とケモカイン受容体活性調節材とを含む組成物
US10953305B2 (en) 2015-08-26 2021-03-23 Icon Health & Fitness, Inc. Strength exercise mechanisms
US10940360B2 (en) 2015-08-26 2021-03-09 Icon Health & Fitness, Inc. Strength exercise mechanisms
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
SG10201911226QA (en) 2015-09-23 2020-01-30 Genentech Inc Optimized variants of anti-vegf antibodies
CA3010056A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
CN120000836A (zh) * 2016-02-08 2025-05-16 约翰霍普金斯大学 树状体-生物粘合剂聚合物水凝胶纳米胶水和其用途
EP3413851B1 (en) 2016-02-10 2023-09-27 Clearside Biomedical, Inc. Packaging
CN109073660B (zh) * 2016-02-29 2022-10-28 麦恩泰科特有限公司 可用于治疗湿性年龄相关性黄斑变性的预测性标志物
JP6664115B2 (ja) * 2016-03-15 2020-03-13 原　英彰 アフリベルセプトによる網膜保護作用
US10441840B2 (en) 2016-03-18 2019-10-15 Icon Health & Fitness, Inc. Collapsible strength exercise machine
US10293211B2 (en) 2016-03-18 2019-05-21 Icon Health & Fitness, Inc. Coordinated weight selection
EP3452165A1 (en) 2016-05-02 2019-03-13 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
US10252109B2 (en) 2016-05-13 2019-04-09 Icon Health & Fitness, Inc. Weight platform treadmill
CA3025258C (en) * 2016-05-25 2024-04-16 Santen Pharmaceutical Co., Ltd. Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
CN110177527B (zh) 2016-08-12 2022-02-01 科尼尔赛德生物医学公司 用于调节药剂递送用针的插入深度的装置和方法
US10661114B2 (en) 2016-11-01 2020-05-26 Icon Health & Fitness, Inc. Body weight lift mechanism on treadmill
US11123411B2 (en) * 2016-12-08 2021-09-21 Gary E. Borodic Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
CN110891611B (zh) 2017-03-22 2024-03-29 阿森迪斯制药公司 水凝胶交联透明质酸前药组合物和方法
CA3061630C (en) 2017-04-27 2021-12-07 The Johns Hopkins University Dendrimer compositions for use in angiography
WO2018204515A1 (en) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
KR102101969B1 (ko) * 2017-09-06 2020-04-22 (주)인벤티지랩 목시덱틴을 포함하는 마이크로 입자 및 이의 제조 방법
EP3707193A1 (en) 2017-11-10 2020-09-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
WO2019103906A1 (en) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
CN108030783A (zh) * 2017-12-27 2018-05-15 广东众生药业股份有限公司 乐伐替尼在制备防治黄斑变性的药物中的用途
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
MX2020010968A (es) * 2018-04-17 2021-01-08 Outlook Therapeutics Inc Formulaciones de bevacizumab tamponadas para usarse en el tratamiento de enfermedades.
KR102192768B1 (ko) * 2018-12-07 2020-12-18 전북대학교산학협력단 식나무 추출물을 포함하는 황반변성의 예방 또는 치료용 약학적 조성물
DE102019112917B4 (de) * 2019-05-16 2021-07-22 Carl Zeiss Meditec Ag Ophthalmologisches Implantat zur Verwendung bei der Behandlung einer Augenkrankheit und Implantationswerkzeug mit einem solchen ophthalmologischen Implantat
CN109966243A (zh) * 2019-05-17 2019-07-05 上海第二工业大学 一种用于眼底黄斑治疗的释药型凝胶及其制备方法
US11141425B2 (en) * 2019-06-27 2021-10-12 University Of Florida Research Foundation, Incorporated Enhancing AAV-mediated transduction of ocular tissues with hyaluronic acid
BR112021026265A2 (pt) 2019-06-27 2022-06-14 Layerbio Inc Métodos e sistemas de entrega de dispositivos oculares
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
DK3861985T3 (da) 2020-02-06 2023-07-24 Ocular Therapeutix Inc Sammensætninger og fremgangsmåder til behandling af øjensygdomme
EP3884929B1 (en) 2020-03-25 2023-06-14 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
EP4171544A4 (en) * 2020-06-26 2024-07-24 Purdue Research Foundation PHARMACEUTICAL FORMULATIONS OF GRISEOFULVINE FOR LONG-TERM EYE ADMINISTRATION
EP4277640A4 (en) * 2021-01-12 2024-12-18 The Regents Of The University Of Michigan Treatment and prevention of dry macular degeneration
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
IL322360A (en) 2023-04-11 2025-09-01 Ocular Therapeutix Inc Intraocular implant containing axitinib iv polymorph

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292475A1 (en) * 2005-12-02 2007-12-20 Campbell Kathleen M Controlled release microparticles
RU2354398C2 (ru) * 2001-07-13 2009-05-10 Оксиджин, Инк. Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2446405A (en) 1945-10-31 1948-08-03 Hazeltine Research Inc Tunable ultra high frequency resonator system
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5264188A (en) * 1991-01-22 1993-11-23 Phillips Petroleum Company Multi-stage hydrotreating process and apparatus
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
HK1042052A1 (zh) * 1999-02-08 2002-08-02 Human Genome Sciences, Inc. 内皮血管生长因子-2
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US6413245B1 (en) * 1999-10-21 2002-07-02 Alcon Universal Ltd. Sub-tenon drug delivery
US20040229960A1 (en) 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
PL223153B1 (pl) * 2002-09-18 2016-10-31 Allergan Inc Urządzenie do wszczepiania implantu okulistycznego
AU2003287381B2 (en) * 2002-10-31 2008-03-06 Celgene Corporation Composition for the treatment of macular degenration
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US7589057B2 (en) * 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
AU2006213673A1 (en) * 2005-02-09 2006-08-17 Santen Pharmaceutical Co., Ltd. Formulations for ocular treatment
CA2601864A1 (en) * 2005-04-08 2006-10-19 Surmodics, Inc. Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease
CN101517068B (zh) * 2005-09-07 2017-02-08 安进弗里蒙特公司 活化素受体样激酶‑1的人单克隆抗体
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US20090221684A1 (en) * 2005-12-22 2009-09-03 Trustees Of Boston University Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof
EP1988889A4 (en) * 2006-01-26 2009-07-22 Acucela Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHAMAL DISEASES AND DISORDERS
JP2009535371A (ja) 2006-05-04 2009-10-01 フォベア、ファルマスティカル、ソシエテ、アノニム 血管新生性疾患の治療のための方法
CN101568332A (zh) * 2006-08-31 2009-10-28 阿布拉科斯生物科学公司 抑制血管生成及治疗血管生成相关疾病的方法
JP2010509369A (ja) 2006-11-10 2010-03-25 ジェネンテック インコーポレイテッド 加齢黄斑変性症を処置するための方法
KR101450356B1 (ko) * 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체
US20080125377A1 (en) * 2006-11-28 2008-05-29 Bartels Stephen P Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
CA2968112C (en) 2016-05-26 2025-09-23 Op-Hygiene Ip Gmbh MAINTENANCE OF A DISPENSER INTENDED FOR AN INSTALLATION WITH MULTIPLE BATHROOMS
US11354735B2 (en) 2019-05-23 2022-06-07 Capital One Services, Llc System and method for interfacing with a decisioning service from a third party domain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2354398C2 (ru) * 2001-07-13 2009-05-10 Оксиджин, Инк. Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний
US20070292475A1 (en) * 2005-12-02 2007-12-20 Campbell Kathleen M Controlled release microparticles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
КОПАЕВА В.Г. под ред. «глазные болезни»// М., «Медицина», 2002, с.323-325. INCORVAIA C et al. 12-month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration// Retina. 2008 Feb;28(2):289-97 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций

Also Published As

Publication number Publication date
EP3524270B1 (en) 2021-09-15
EP2307055B1 (en) 2016-01-06
CN102159246A (zh) 2011-08-17
US10363214B2 (en) 2019-07-30
EP2664347B1 (en) 2019-03-13
RU2668371C2 (ru) 2018-09-28
AU2009271168B2 (en) 2014-08-14
JP2011528656A (ja) 2011-11-24
ES2720882T3 (es) 2019-07-25
JP2016169233A (ja) 2016-09-23
US20100015158A1 (en) 2010-01-21
JP6009511B2 (ja) 2016-10-19
RU2521338C2 (ru) 2014-06-27
EP2664347A1 (en) 2013-11-20
ES2897560T3 (es) 2022-03-01
EP3950002A1 (en) 2022-02-09
WO2010009034A3 (en) 2010-05-06
EP2307055A2 (en) 2011-04-13
ES2574706T3 (es) 2016-06-21
CA2731270C (en) 2017-05-30
CA2731270A1 (en) 2010-01-21
RU2011105409A (ru) 2012-08-27
RU2018133133A (ru) 2020-03-19
US20140322206A1 (en) 2014-10-30
US8821870B2 (en) 2014-09-02
KR20110047196A (ko) 2011-05-06
CN107412778A (zh) 2017-12-01
JP2014237713A (ja) 2014-12-18
WO2010009034A2 (en) 2010-01-21
JP6132964B2 (ja) 2017-05-24
AU2009271168A1 (en) 2010-01-21
EP3524270A1 (en) 2019-08-14
RU2014115647A (ru) 2015-10-27
BRPI0915981A2 (pt) 2020-08-18
US20190336441A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
RU2521338C9 (ru) Способ лечения атрофической возрастной макулярной дегенерации
RU2440102C2 (ru) Системы доставки лекарственного средства внутрь глаза
US20100098772A1 (en) Drug delivery systems and methods for treating neovascularization
AU2018211329A1 (en) Intraocular sustained release drug delivery systems and methods for treating ocular conditions
HK40012677A (en) Treating atrophic age related macular degeneration
HK1190092A (en) Bevacizumab for use in a method for treating atrophic age related macular degeneration
AU2014202336A1 (en) Intraocular drug delivery systems
HK1190092B (en) Bevacizumab for use in a method for treating atrophic age related macular degeneration

Legal Events

Date Code Title Description
TH4A Reissue of patent specification
TK4A Correction to the publication in the bulletin (patent)

Free format text: AMENDMENT TO CHAPTER -FG4A- IN JOURNAL: 18-2014